CAR T cells have been developed to target the antigens B7-H3 (CD276), GD2, EGFR, IL13Ra2 and HER2 in a range of brain cancers such as medulloblastoma, glioma and ependymoma [220]. This evidence concerns the gene CD276 and glioma.